RLAY
Relay Therapeutics, Inc.
There isn't enough reported data to score RLAY yet.
RLAY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RLAY's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
RLAY PE Valuation
RLAY has no meaningful PE right now: it lost money over the past year.
RLAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RLAY's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
RLAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.50 | +$0.22 |
| Q2 2026 | -$1.56 | +$0.36 |
| Q1 2026 | -$1.56 | +$0.64 |
| Q4 2025 | -$1.61 | +$0.75 |
| Q3 2025 | -$1.72 | +$0.90 |
| Q2 2025 | -$1.92 | +$0.61 |
| Q1 2025 | -$2.20 | +$0.45 |
| Q4 2024 | -$2.36 | +$0.45 |
RLAY is still losing money, but far less than before: $1.50 per share over the past year, against $3.92 at its worst in early 2022.
RLAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $350K | -48% |
| Q1 2026 | $3M | -61% |
| Q1 2025 | $7.7M | -23% |
| Q1 2024 | $10M | +4328% |
| Q3 2023 | $25.2M | +7226% |
| Q2 2023 | $119K | -67% |
| Q1 2023 | $226K | -46% |
| Q4 2022 | $253K | -99% |
RLAY's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -25950% | -14599 points |
| Q1 2026 | -2620% | -1515 points |
| Q4 2025 | -866% | N/A |
| Q2 2025 | -11351% | N/A |
| Q1 2025 | -1105% | -202 points |
| Q1 2024 | -903% | +43866 points |
| Q3 2023 | -292% | +24677 points |
| Q2 2023 | -89118% | -67800 points |
RLAY's operating margin was −25950% last quarter, down 24845 points from the same quarter a year ago.
RLAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$63.9M | -$1.8M |
| Q4 2025 | -$44.9M | +$13M |
| Q3 2025 | -$62.1M | +$13.2M |
| Q2 2025 | -$55.3M | +$10.6M |
| Q1 2025 | -$73.6M | -$21.5M |
| Q4 2024 | -$57.9M | +$31.4M |
| Q3 2024 | -$75.3M | +$677K |
| Q2 2024 | -$65.8M | +$4.3M |
RLAY has burned cash in almost every quarter: −$226M over the past year, against −$273M the year before.
RLAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +16.3M shares |
| 1 year | +27% | +46.8M shares |
| 3 years | +79% | +96.9M shares |
| 5 years | +136% | +126M shares |
RLAY has 219M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q1 2020 | — |
| Q4 2019 | — |
RLAY Net Leverage
RLAY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RLAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 43.1 | Neutral |
RLAY's weekly RSI is 55 (neutral) and its Stochastic is 43 (neutral).
RLAY PE vs Healthcare Sector
RLAY has no meaningful PE right now: it lost money over the past year.
RLAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.0 | 0.6% above |
| 20 week MA | $18.7 | 3.4% below |
| 50 week MA | $14.2 | 27% above |
| 100 week MA | $9.17 | 97% above |
| 200 week MA | $9.50 | 90% above |
RLAY's trend is mixed: it's above four of its five weekly moving averages, and 90% above its 200-week average.
RLAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.0 | $46.9 | +6.6% |
| 2021 | $46.9 | $33.4 | -29% |
| 2022 | $33.4 | $14.6 | -56% |
| 2023 | $14.6 | $11.0 | -25% |
| 2024 | $11.0 | $4.36 | -60% |
| 2025 | $4.36 | $8.56 | +96% |
| 2026 YTD | $8.56 | $18.1 | +111% |
RLAY is up 111% so far in 2026, after finishing lower in four of the previous six years.